Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Gains from Sales and Divestitures (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $887124.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $887124.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $887124.0, a N/A change, with the full-year FY2025 number at $887124.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $887124.0 for Q4 2025 at Soleno Therapeutics, up from $825607.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $887124.0 in Q4 2025 to a low of $800500.0 in Q1 2025.